InterMune Revenue and Competitors
Estimated Revenue & Valuation
- InterMune's estimated annual revenue is currently $15.7M per year.
- InterMune's estimated revenue per employee is $155,000
Employee Data
- InterMune has 101 Employees.
- InterMune grew their employee count by -4% last year.
InterMune's People
| Name | Title | Email/Phone |
|---|
InterMune Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is InterMune?
InterMune is a values-driven organization that works to embody integrity, passion, accountability, creativity and teamwork in bringing new treatments and hope to patients and families around the world. Our focus is research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, unpredictable and ultimately fatal lung disease. Pirfenidone, the only medicine approved for IPF, is marketed by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.
keywords:N/A
N/A
Total Funding
101
Number of Employees
$15.7M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
InterMune News
That pirfenidone is primarily metabolized by CYP1A2 was a novel discovery by Intermune and was not known prior to the DDI patents' priority...
... Inc., Lilly, InterMune, Jina Pharmaceuticals, SteriMax, and XGen Pharmaceuticals DJB, Inc., among other domestic and global players.
Merck; Pfizer; Roche; Intermune; Galectin Therapeutics; La Jolla Pharmaceutical Company; Prometic Life-sciences Inc. Bioline Rx Ltd; Genzyme Corporation.
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $21.2M | 101 | 6% | N/A |
#2 | $24.1M | 101 | 7% | N/A |
#3 | $15M | 101 | 2% | $15.4M |
#4 | $15M | 101 | -3% | N/A |
#5 | $21.2M | 101 | 4% | N/A |